Clinical Trial

A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II study. All patients are stage IV non-squamas non-small cell lung cancer(NSCLC) with malignant pleura effusion, Eastern Cooperative Oncology Group (ECOG) performance status 0-2. The purpose of this study is to evaluate the efficacy and safety of AK112 in combination with chemotherapy in patients with NSCLC with malignant pleura effusion.
Trial Details
NCT Number NCT06769295
Lead Sponsor Sichuan University
Conditions Lung Cancer, Non-Small Cell
Enrollment 28 participants
Start Date 2025-02-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-10